CN104271155A - 聚阴离子卡波姆和Env多肽的免疫原性复合物及其制造方法和用途 - Google Patents

聚阴离子卡波姆和Env多肽的免疫原性复合物及其制造方法和用途 Download PDF

Info

Publication number
CN104271155A
CN104271155A CN201280055731.5A CN201280055731A CN104271155A CN 104271155 A CN104271155 A CN 104271155A CN 201280055731 A CN201280055731 A CN 201280055731A CN 104271155 A CN104271155 A CN 104271155A
Authority
CN
China
Prior art keywords
polypeptide
env
hiv
methods
polyanion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280055731.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·W·巴尼特
A·德伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104271155A publication Critical patent/CN104271155A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201280055731.5A 2011-11-14 2012-11-14 聚阴离子卡波姆和Env多肽的免疫原性复合物及其制造方法和用途 Pending CN104271155A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559512P 2011-11-14 2011-11-14
US61/559,512 2011-11-14
PCT/US2012/065113 WO2013074696A1 (en) 2011-11-14 2012-11-14 Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof

Publications (1)

Publication Number Publication Date
CN104271155A true CN104271155A (zh) 2015-01-07

Family

ID=47222339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280055731.5A Pending CN104271155A (zh) 2011-11-14 2012-11-14 聚阴离子卡波姆和Env多肽的免疫原性复合物及其制造方法和用途

Country Status (11)

Country Link
US (1) US9393300B2 (https=)
EP (1) EP2780035A1 (https=)
JP (1) JP2014533290A (https=)
CN (1) CN104271155A (https=)
AU (1) AU2012340035A1 (https=)
BR (1) BR112014011560A2 (https=)
CA (1) CA2855826A1 (https=)
MX (1) MX2014005548A (https=)
RU (1) RU2014124154A (https=)
WO (1) WO2013074696A1 (https=)
ZA (1) ZA201402910B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
ATE112687T1 (de) 1988-09-13 1994-10-15 Chiron Corp Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
EP0688205A1 (en) * 1993-03-11 1995-12-27 Secretech, Inc. Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
CN1111540C (zh) 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
JP2006509039A (ja) * 2002-12-03 2006-03-16 ユニバーシティ オブ マサチューセッツ 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
AU2006304725B2 (en) * 2005-10-17 2012-03-15 Novartis Ag Multiclade HIV vaccines
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CURRAN R M ET AL: "Vaginal delivery of the recombinant HIV-1 clade-c trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune response", 《VACCINE》 *
DAVID J LEWIS ET AL: "Phase I randomised Clinical Trial of an HIV-1 CN54,Clade C Trimeric Envelop Vaccine Candidate Delivered Vaginally", 《PLOS ONE》 *
GEORGE KRASHIAS ET AL: "Potent adaptive immune responses induced against HIV-1 gp140 and influenza", 《VACCINE》 *
M P CRANAGE ET AL: "Repeated vaginal administration of trimeric HIV-1 clade C gp140 inducs serum and mucosal antibody responses", 《MUCOSAL IMMUNOLOGY》 *

Also Published As

Publication number Publication date
JP2014533290A (ja) 2014-12-11
US20140314703A1 (en) 2014-10-23
CA2855826A1 (en) 2013-05-23
US9393300B2 (en) 2016-07-19
WO2013074696A1 (en) 2013-05-23
MX2014005548A (es) 2014-08-21
BR112014011560A2 (pt) 2017-05-09
RU2014124154A (ru) 2015-12-27
AU2012340035A1 (en) 2014-04-17
EP2780035A1 (en) 2014-09-24
ZA201402910B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
US9393300B2 (en) Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof
Saunders et al. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
US12053519B2 (en) HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
Vaine et al. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity
JP6165612B2 (ja) コンセンサス／先祖免疫原
US8609109B2 (en) HIV vaccine formulations
US7172761B2 (en) Polyvalent immunogen
US7195768B2 (en) Polyvalent immunogen
van Diepen et al. Prime-boost immunizations with DNA, modified vaccinia virus Ankara, and protein-based vaccines elicit robust HIV-1 tier 2 neutralizing antibodies against the CAP256 superinfecting virus
US6447778B1 (en) Peptide compositions for the treatment of HIV infection
Bi et al. An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses
CA2472579A1 (en) Hiv vaccine and method of use
EP0762895B1 (en) Synthetic vaccine for protection against human immunodeficiency virus infection
Wagner et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques
JPH07501052A (ja) ウイルスエンベロープタンパク質と糖タンパク質の中和エピトープに相当するペプチドとの間の相乗作用によるウイルス感染に対する防御の誘発
EP0472706B1 (en) Induction of protection against viral infection
JP2010530356A (ja) 急性伝染ｈｉｖエンベロープ・サイン
Oxford et al. Challenges and strategies for AIDS vaccine development
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
Purwar Design and characterization of HIV-1 Env derived immunogens
Chege Pre-clinical assessment of novel candidate HIV-1 vaccines using the Chacma baboon
Newman et al. Characterization of Immune Responses Elicited by an Experimental Facilitated-DNA Vaccine for Human Immunodeficiency Virus Type-1 (HIV-1)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150107

WD01 Invention patent application deemed withdrawn after publication